Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- NCR -12.1%, GNTX -8%, GE -6.8%, TACO -5.8%, WERN -4.5%, CLF -3.9%,ATHN -3.4%, ISRG -3.2%, ISRG -3.2%, PFPT -2.7%, PG -1.7%, ETFC-1.6%, (also to acquire Trust Company of America)
Other news:
- DRRX -55.3% (top-line results from the PERSIST Phase 3 Trial of POSIMIR (SABER-Bupivacaine) did not meet primary efficacy endpoint)
- BPMX -34.4% (low cap / thinly traded name; files for $40.25 mln mixed securities shelf offering)
- CAPR -7.9% (Capricor Therapeutics entered into $14 mln common stock 'at the market offering' sales agreement )
- AAXN -7.8% (lower after disclosing SEC letter - to review 10-K)
- CELG -6% (announces that the GED-0301 phase III REVOLVE trial in Crohn's disease and the extension trial will discontinue following recommendation from Data Monitoring Committee)
- DBD -3.2% (following NCR results)
- ZGNX -1.4% (extending this afternoon's move higher)
- RXDX -0.9% (prices 10 mln shares of common stock at $16.00 per share)
Analyst comments:
- KMB -1.8% (downgraded to Underweight from Neutral at JP Morgan)
- HMY -1.8% (downgraded to Neutral from Buy at BofA/Merrill)
- REGN -1.7% (downgraded to Underweight from Equal Weight at Barclays)